Recently, the Shanghai Municipal Commission of Economy and Informatization announced the second‑batch list of Shanghai Specialized, Refined, Differential and Innovative (SRDI) SMEs for 2026. Shanghai Escugen Biotechnology Co., Ltd. has obtained the SRDI SME certification through its continuous innovation and deep expertise in biomedical research and development.
The SRDI SME designation is an authoritative accreditation for high‑quality enterprises granted upon expert review and comprehensive evaluation, in accordance with the Measures for the Gradient Cultivation of High‑Quality Small‑ and Medium‑Sized Enterprises (MIIT Enterprise〔2026〕No.2) issued by the Ministry of Industry and Information Technology and the Implementation Rules for the Gradient Cultivation of High‑Quality Small‑ and Medium‑Sized Enterprises in Shanghai (SH ECO‑INF Spec〔2022〕No.8) released by the Shanghai Municipal Commission of Economy and Informatization. It represents national guidance for small‑ and medium‑sized enterprises to pursue high‑quality development featuring specialization, refinement, differentiation and innovation. As the backbone of high‑quality SMEs, SRDI SMEs recognize outstanding enterprises that dig deep into niche segments, hold independent core technologies and possess strong innovation competitiveness. They also constitute key innovation entities for stabilizing industrial and supply chains and fostering new‑quality productive forces.
Escugen has long focused on the R&D of globally leading Best‑in‑Class / First‑in‑Class innovative drugs, with a primary focus on developing novel therapeutics for oncology and autoimmune diseases. This achievement marks official authoritative recognition of Escugen’s technological barriers, R&D system and industrialization value. Going forward, Escugen will take this milestone as a new starting point, remain committed to the SRDI development path, continuously increase its R&D investment ratio, strengthen the foundation of independent core technologies, accelerate the clinical progress of its in‑house pipeline candidates, strive to benefit more patients across the globe, and contribute to the high‑quality development of the biomedical industrial chain.
About Escugen
Shanghai Escugen Biotechnology Co., Ltd. was established in 2017 in Zhangjiang High-Tech Park, Pudong New Area, Shanghai. The company focuses on innovative drug development in the fields of oncology and autoimmune diseases. The founding team has decades of R&D experience in both international and domestic biopharmaceutical companies. The R&D team is professionally comprehensive, covering antibody engineering, conjugation technology, CMC, and clinical development, with an average of over 10 years of industry experience.
Escugen has pioneered the EZWi-Fit® linker-payload technology platform with global intellectual property rights. The clinical safety and efficacy of ADCs based on this platform technology have been preliminarily validated through ongoing clinical trials. Recently, multiple domestic and international partners have also advanced innovative target ADCs based on this platform into clinical trial phases.
